ClinicalTrials.gg
Not yet recruitingNCT07517705MRD-XRTUpdated Nov 6, 2026

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Low-Dose Radiation Therapy (LDRT) and Standard Frontline Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Lymphoma, Large B-Cell, Diffuse by University of Nebraska — 1 open to participants now, 1 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · University of Nebraska.

Planned enrollment
4th of 11
50 · median 44
Started
2026
the only one that year
Phase 2
11 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Lymphoma, Large B-Cell, Diffuse by University of Nebraska, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 11 in phase 2, and was the 15th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 15 studies in Lymphoma, Large B-Cell, Diffuse by University of Nebraska is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, Large B-Cell, Diffuse by University of Nebraska, or all of them as a file.
02

Study summary

This prospective Phase IIA feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline R-chemoimmunotherapy. Circulating tumor DNA (ctDNA)-based MRD testing and interim positron emission tomography (PET) imaging after two cycles of therapy are used to guide treatment decisions. Patients with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard systemic therapy. Patients with undetectable MRD, or detectable MRD without targetable residual disease, continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

Read the detailed description

Diffuse large B-cell lymphoma (DLBCL) is commonly treated with frontline R-chemoimmunotherapy regimens such as R-CHOP or related combinations. Interim positron emission tomography (PET) imaging provides information about treatment response, while circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing allows assessment of molecular residual disease during treatment.

This prospective, non-randomized Phase IIA feasibility study evaluates the integration of ctDNA-based MRD testing and interim PET imaging into frontline treatment decisions for patients with DLBCL. Approximately 50 participants are expected to enroll.

Following two cycles of frontline R-chemoimmunotherapy, participants undergo protocol-specified MRD testing and interim PET assessment. Participants with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy are assigned to Arm A and receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard frontline chemoimmunotherapy.

Participants with undetectable MRD, as well as those with detectable MRD but without targetable residual disease, are assigned to Arm B and continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

The primary objective is to evaluate the feasibility of this MRD-adapted strategy, including successful completion of MRD testing after cycle 2 and delivery of protocol-directed LDRT to eligible MRD-positive participants. Secondary assessments include treatment response, progression-free survival, overall survival, the impact of LDRT on systemic treatment delivery, and patient-reported quality of life.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Minimal Residual Disease
  • ctDNA
  • PET-CT
  • MRD-guided therapy
  • Low-Dose Radiation Therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥19 years of age
  2. -proven newly diagnosed DLBCL, transformed from indolent lymphoma, Follicular lymphoma grade 3B, post-transplant lymphoproliferative disorder, or any other subtypes of Large B-cell lymphoma under WHO-HAEM5 classification who are eligible and plan to receive 6 cycles of R-chemoimmunotherapy. Note: patients may receive up to one cycle of R-chemoimmunotherapy prior to enrollment.
  3. Planned to receive 6 cycles of frontline R-chemoimmunotherapy for diseases mentioned in criterion 2
  4. Presence of on imaging, nodal lesion >1.5cm or extra-nodal lesion >1 cm prior to initiation of R-chemoimmunotherapy
  5. Availability of sufficient and viable baseline FFPE tumor tissue to allow development of a personalized MRD assay

Exclusion criteria

Exclusion Criteria:

  1. Limited stage (Ann Arbor stage I-II) DLBCL, requiring less than 6 cycles of R-chemoimmunotherapy
  2. Primary or secondary CNS lymphoma
  3. Subject has exceeded maximum lifelong cumulative doses of radiation therapy or is unsafe for radiation therapy as determined by the investigator and/or radiation oncologist
  4. Pregnant and lactating patients
  5. Has received two or more cycles of R-chemoimmunotherapy relating to this disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Arm- A: MRD-Detectable with Protocol-Directed LDRT

    Participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) to targetable residual disease sites in addition to standard frontline chemoimmunotherapy.

    Radiation: Low-Dose Radiation Therapy (LDRT) · Other: Standard Frontline Chemoimmunotherapy

  • Active comparator
    Arm B: Standard Therapy Without Protocol-Directed LDRT

    Participants with undetectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy, or participants with detectable MRD but without residual PET-avid or measurable disease suitable for radiation therapy, continue standard frontline chemoimmunotherapy without protocol-directed low-dose radiation therapy (LDRT).

    Other: Standard Frontline Chemoimmunotherapy

Interventions

  • RadiationLow-Dose Radiation Therapy (LDRT)

    Low-dose radiation therapy delivered to residual PET-avid disease sites identified after interim assessment with PET imaging and MRD testing.

  • OtherStandard Frontline Chemoimmunotherapy

    Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician.

06

What researchers measure

Primary outcomes

  1. Feasibility of Real-Time MRD-Guided Treatment Strategy

    Feasibility will be assessed by the proportion of enrolled patients who successfully complete protocol-specified MRD testing after two cycles of chemoimmunotherapy and, among patients with detectable MRD, the proportion who successfully receive protocol-defined low-dose radiation therapy (LDRT). Feasibility will be considered acceptable if at least 80% of enrolled patients complete MRD testing and at least 80% of ctDNA-positive patients receive LDRT.

    Time frame: From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).

Secondary outcomes

  1. Overall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates

    The proportion of participants achieving complete response (CR) or partial response (PR), with complete response rate assessed separately. Response will be evaluated using PET/CT imaging according to Lugano 2014 criteria.

    Time frame: At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

  2. Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from initiation of frontline therapy until disease progression or death from any cause. PFS will be estimated using the Kaplan-Meier method.

    Time frame: From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.

  3. Overall Survival (OS)

    Overall survival is defined as the time from initiation of frontline therapy until death from any cause. OS will be estimated using the Kaplan-Meier method.

    Time frame: From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.

  4. Impact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy

    The impact of protocol-directed low-dose radiation therapy (LDRT) on the delivery of planned systemic chemoimmunotherapy will be assessed by treatment delays, dose reductions, omitted chemotherapy cycles, or premature discontinuation of systemic therapy attributable to LDRT.

    Time frame: From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

  5. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Patient-reported quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), evaluating global health status, functional domains, and symptoms.

    Time frame: At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2031, 50 months later.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 50 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jun 2026 → Dec 2026, primary completion Nov 2030 → Feb 2031 and completion Nov 2032 → Feb 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 8, 2026
StartEst.
Dec 12, 2026was Jun 2026
Primary completionEst.
Feb 12, 2031was Nov 2030
CompletionEst.
Feb 12, 2033was Nov 2032
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 12, 2026→Dec 12, 2026
Nov 6, 2026
Primary completion
Nov 12, 2030→Feb 12, 2031
Nov 6, 2026
Study completion
Nov 12, 2032→Feb 12, 2033
Nov 6, 2026
Interventions
Arm changed Arm- A: MRD-Detectable with Protocol-Directed LDRT Consideration→Arm- A: MRD-Detectable with Protocol-Directed LDRT; Arm- B: MRD-Undetectable Standard Therapy→Arm B: Standard Therapy Without Protocol-Directed LDRT
Nov 6, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameFeasibility of Real-Time MRD-Guided Treatment StrategyFrom initiation of study treatment through completion of frontline therapy (approximately 6 months) → From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
  • DescriptionFeasibility of Real-Time MRD-Guided Treatment Strategy: how it is measured was reworded
Nov 6, 2026
Secondary outcomes
5 time frame changed, 5 description edited
What changed in the outcomes
  • Time frameOverall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) RatesFrom initiation of study treatment through completion of frontline therapy (approximately 6 months) → At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
  • Time frameProgression-Free Survival (PFS)From initiation of study treatment until disease progression or death, assessed up to 24 months → From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
  • Time frameOverall Survival (OS)From initiation of study treatment until death from any cause, assessed up to 24 months → From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
  • Time frameImpact of Low-Dose Radiation Therapy on Delivery of Systemic ChemoimmunotherapyFrom initiation of study treatment through completion of frontline Chemoimmunotherapy (approximately 6 months) → From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
  • Time frameEuropean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)From baseline through end of treatment, assessed up to 24 months → At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
  • DescriptionEuropean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): how it is measured was reworded
  • DescriptionImpact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy: how it is measured was reworded
  • DescriptionOverall Survival (OS): how it is measured was reworded
  • DescriptionOverall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates: how it is measured was reworded
  • DescriptionProgression-Free Survival (PFS): how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Jun 12, 2026→Dec 12, 2026
    Primary completion Nov 12, 2030→Feb 12, 2031
    Study completion Nov 12, 2032→Feb 12, 2033
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameFeasibility of Real-Time MRD-Guided Treatment StrategyFrom initiation of study treatment through completion of frontline therapy (approximately 6 months) → From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
    • DescriptionFeasibility of Real-Time MRD-Guided Treatment Strategy: how it is measured was reworded
    Secondary outcomes 5 time frame changed, 5 description edited
    What changed in the outcomes
    • Time frameOverall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) RatesFrom initiation of study treatment through completion of frontline therapy (approximately 6 months) → At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
    • Time frameProgression-Free Survival (PFS)From initiation of study treatment until disease progression or death, assessed up to 24 months → From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
    • Time frameOverall Survival (OS)From initiation of study treatment until death from any cause, assessed up to 24 months → From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
    • Time frameImpact of Low-Dose Radiation Therapy on Delivery of Systemic ChemoimmunotherapyFrom initiation of study treatment through completion of frontline Chemoimmunotherapy (approximately 6 months) → From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
    • Time frameEuropean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)From baseline through end of treatment, assessed up to 24 months → At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
    • DescriptionEuropean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): how it is measured was reworded
    • DescriptionImpact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy: how it is measured was reworded
    • DescriptionOverall Survival (OS): how it is measured was reworded
    • DescriptionOverall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates: how it is measured was reworded
    • DescriptionProgression-Free Survival (PFS): how it is measured was reworded
    Interventions Arm changed Arm- A: MRD-Detectable with Protocol-Directed LDRT Consideration→Arm- A: MRD-Detectable with Protocol-Directed LDRT; Arm- B: MRD-Undetectable Standard Therapy→Arm B: Standard Therapy Without Protocol-Directed LDRT
    + 5 other changes: identifiers, verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07517705
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Dec 12, 2026 (estimated)
Primary completion
Feb 12, 2031 (estimated)
Completion
Feb 12, 2033 (estimated)
Last update
Nov 6, 2026

Study contacts

Krishna vamsi Gottipati, MS
Contact
krgottipati@unmc.edu
(402) 5593518
IIT Office Clinical Trails Office
Contact
IITOFFICE@unmc.edu
(402) 5590963
Snegha Ananth, MBBS
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion